Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Psychiatric Education (January) | 2023

View Archived Issues

Learning Objectives, Psychiatric Education, TCPR, January 2023

January 1, 2023

After reading these articles, you should be able to do the following.

Viibryd Goes Generic, But Is It Worth Prescribing?

January 1, 2023

Chris Aiken, MD

Goodbye Viibryd, hello vilazodone. This novel medication has missed the mark in a lot of trials, but it still has a narrow niche in the crowded field of antidepressants.

20 Years of The Carlat Report

January 1, 2023

Daniel Carlat, MD

Twenty years ago, Danny Carlat walked away from industry-funded education and started The Carlat Report. Here he looks back on pivotal moments that have changed the field and shares his perspective on the controversies of today.

Aripiprazole-Related Psychotic Exacerbations

January 1, 2023

Brian Miller, MD, PhD, MPH.

This study identifies a common clinical scenario where aripiprazole may trigger psychotic symptoms.

Should We Use Two Antidepressants to Treat Unipolar Depression?

January 1, 2023

Paul Riordan, MD.

Antidepressant combinations come up wanting in this meta-analysis, with one possible ray of hope.

DBT Skills May Reduce Polypharmacy in Borderline Personality Disorder

January 1, 2023

Simon M. Dosovitz, MD

This real-world study finds that patients with BPD are able to trade pills for skills, with substantial reductions in a controversial class of medications.

Pimavanserin Improves Negative Symptoms of Schizophrenia

January 1, 2023

Brian Miller, MD, PhD, MPH

Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of
schizophrenia.